David W. Boyer, who serves as the Chief Corporate Affairs Officer for Neurocrine Biosciences Inc., executed a sale of company common stock valued at approximately $609,023 on May 26, 2026. The disposition involved 3,888 shares of the firm's common stock. These shares were sold through multiple transactions, with prices ranging from $155.81 to $157.62 per share. The calculated weighted average sale price for these units was $156.6418.
It is important to note that this specific sale was executed under the framework of a Rule 10b5-1 trading plan, which Mr. Boyer initially adopted on February 23, 2026. Company policy stipulates that reporting persons are restricted from making any amendments or modifications to a 10b5-1 trading plan after its initial adoption.
The timing of this sale coincides with several notable developments for Neurocrine Biosciences. The stock was observed trading near its 52-week high, reaching $162.39, and had generated a strong return of 27% over the preceding year. Despite this recent upward momentum, an analysis provided by InvestingPro suggested that the stock might be undervalued relative to its calculated Fair Value, indicating potential upside potential.
Following the completion of the transaction on May 26, Mr. Boyer's direct holdings in Neurocrine Biosciences common stock were reduced but still substantial. His remaining total ownership includes 7,799 shares. This balance incorporates an additional 106 shares that he acquired on February 27, 2026, through the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
Beyond executive activity and valuation metrics, recent corporate disclosures paint a picture of strong operational success for Neurocrine. The company reported robust performance during the first quarter of 2026, successfully surpassing anticipated earnings expectations. Specifically, the firm announced an Earnings Per Share (EPS) of $1.94 per share. This figure represented a significant deviation from the projected EPS of $1.17, resulting in an earnings surprise of 65.81%. Furthermore, quarterly revenue also exceeded forecasts, totaling $811 million when analysts had expected $766.85 million.
From a strategic growth perspective, Neurocrine Biosciences finalized a substantial acquisition: a $2.9 billion purchase of Soleno Therapeutics Inc. This deal involved a cash tender offer and successfully integrated VYKAT XR into the company's existing product portfolio, making Soleno a wholly owned subsidiary. Complementing this expansion, Bernstein SocGen Group initiated coverage on Neurocrine with an 'outperform' rating. The group highlighted the significant potential inherent in two of the firm's key medicines: Crenessity and Ingrezza. These drugs have respective loss-of-exclusivity dates set for 2035 and 2038.
The company also provided compelling clinical data at a recent industry conference. The presentation indicated that a high percentage of patients, specifically 96% of those diagnosed with mild tardive dyskinesia, experienced improvement after commencing treatment with INGREZZA. For deeper insights into the valuation and overall performance metrics of Neurocrine’s holdings, investors have access to comprehensive Pro Research Reports covering this stock and over 1,400 other US equities on InvestingPro.